BG107065A - Кристална форма на циталопрам - Google Patents

Кристална форма на циталопрам Download PDF

Info

Publication number: BG107065A
Authority: BG; Bulgaria
Prior art keywords: citalopram; base; salt; hydrobromide; hydrochloride
Prior art date: 2000-03-13

Application number

BG107065A

Other languages

Bulgarian (bg)

English (en)

Inventor

Hans Petersen

Klaus Bogeso

Per Holm

Original Assignee

H.Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-13

Filing date

2002-09-05

Publication date

2003-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG107065(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-09-05 Application filed by H.Lundbeck A/S filed Critical H.Lundbeck A/S

2003-05-30 Publication of BG107065A publication Critical patent/BG107065A/bg

Links

WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 title claims abstract description 107
229960001653 citalopram Drugs 0.000 title claims abstract description 100
150000003839 salts Chemical class 0.000 claims abstract description 43
239000000203 mixture Substances 0.000 claims abstract description 35
238000000034 method Methods 0.000 claims abstract description 34
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims abstract description 20
238000002360 preparation method Methods 0.000 claims abstract description 13
239000002585 base Substances 0.000 claims description 58
238000006243 chemical reaction Methods 0.000 claims description 32
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
239000012458 free base Substances 0.000 claims description 12
125000000217 alkyl group Chemical group 0.000 claims description 10
239000002671 adjuvant Substances 0.000 claims description 9
239000008187 granular material Substances 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
238000000746 purification Methods 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 6
239000012535 impurity Substances 0.000 claims description 6
WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 claims description 5
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 5
XAJMJYPAJNLKIS-UHFFFAOYSA-N [5-(4-bromophenyl)furan-2-yl]methanamine Chemical compound O1C(CN)=CC=C1C1=CC=C(Br)C=C1 XAJMJYPAJNLKIS-UHFFFAOYSA-N 0.000 claims description 5
125000003710 aryl alkyl group Chemical group 0.000 claims description 5
229960000584 citalopram hydrobromide Drugs 0.000 claims description 5
150000002825 nitriles Chemical group 0.000 claims description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
238000001556 precipitation Methods 0.000 claims description 4
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
238000007907 direct compression Methods 0.000 claims description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
229910002651 NO3 Inorganic materials 0.000 claims description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
229910019142 PO4 Inorganic materials 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
239000010452 phosphate Substances 0.000 claims description 2
239000002244 precipitate Substances 0.000 claims description 2
125000003107 substituted aryl group Chemical group 0.000 claims description 2
239000000155 melt Substances 0.000 claims 1
239000000935 antidepressant agent Substances 0.000 abstract description 5
238000009472 formulation Methods 0.000 abstract description 3
WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 abstract description 2
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
239000003826 tablet Substances 0.000 description 29
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
239000011701 zinc Substances 0.000 description 16
239000003054 catalyst Substances 0.000 description 14
239000002904 solvent Substances 0.000 description 13
150000001875 compounds Chemical class 0.000 description 12
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 11
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 9
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
125000004093 cyano group Chemical group *C#N 0.000 description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
239000002253 acid Substances 0.000 description 8
-1 hydrobromide Chemical class 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000003197 catalytic effect Effects 0.000 description 6
238000001816 cooling Methods 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
239000012071 phase Substances 0.000 description 6
150000001408 amides Chemical class 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
238000005469 granulation Methods 0.000 description 5
230000003179 granulation Effects 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
230000001430 anti-depressive effect Effects 0.000 description 4
229940005513 antidepressants Drugs 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
230000008025 crystallization Effects 0.000 description 4
239000012024 dehydrating agents‎ Substances 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 3
239000013078 crystal Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical group C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
244000309464 bull Species 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
229940099112 cornstarch Drugs 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
239000012467 final product Substances 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000012454 non-polar solvent Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
239000008096 xylene Substances 0.000 description 2
CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
CGVBIXZVEMXIQU-UHFFFAOYSA-N 3-[1-(4-fluorophenyl)-3h-2-benzofuran-1-yl]-n,n-dimethylpropan-1-amine Chemical class O1CC2=CC=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 CGVBIXZVEMXIQU-UHFFFAOYSA-N 0.000 description 1
208000032963 Capsule physical issue Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
150000001491 aromatic compounds Chemical class 0.000 description 1
238000009835 boiling Methods 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000006193 diazotization reaction Methods 0.000 description 1
JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000012155 injection solvent Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
239000002608 ionic liquid Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
238000007909 melt granulation Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Laminated Bodies (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Silicates, Zeolites, And Molecular Sieves (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Manufacture Of Macromolecular Shaped Articles (AREA)
Plural Heterocyclic Compounds (AREA)

BG107065A 2000-03-13 2002-09-05 Кристална форма на циталопрам BG107065A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200000402		2000-03-13
DKPCT/DK00/00183		2000-04-13
PCT/DK2001/000137 WO2001068627A1 (en)	2000-03-13	2001-02-28	Crystalline base of citalopram

Publications (1)

Publication Number	Publication Date
BG107065A true BG107065A (bg)	2003-05-30

Family

ID=8159320

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107065A BG107065A (bg)	2000-03-13	2002-09-05	Кристална форма на циталопрам

Country Status (41)

Country	Link
US (7)	US20010031784A1 (is)
EP (2)	EP1169314B2 (is)
JP (1)	JP2003527383A (is)
KR (1)	KR20020080486A (is)
CN (2)	CN1258530C (is)
AR (1)	AR029811A1 (is)
AT (3)	ATE223396T1 (is)
AU (2)	AU746664B2 (is)
BE (1)	BE1013210A3 (is)
BG (1)	BG107065A (is)
BR (1)	BR0109373A (is)
CA (2)	CA2411732A1 (is)
CH (2)	CH691477A5 (is)
CZ (1)	CZ292077B6 (is)
DE (7)	DE20007303U1 (is)
DK (3)	DK173903B1 (is)
EA (1)	EA200200972A1 (is)
ES (3)	ES2180471T3 (is)
FI (2)	FI20010156A0 (is)
FR (1)	FR2806086B1 (is)
GB (2)	GB2357762B (is)
GR (1)	GR1003796B (is)
HR (1)	HRP20020756A2 (is)
HU (3)	HU0001581D0 (is)
IE (1)	IES20010109A2 (is)
IL (2)	IL147339A (is)
IS (1)	IS5841A (is)
IT (2)	IT1319645B1 (is)
MX (1)	MXPA02008793A (is)
NL (2)	NL1016435C1 (is)
NO (2)	NO312031B1 (is)
PL (1)	PL360158A1 (is)
PT (2)	PT1169314E (is)
SE (2)	SE517136C2 (is)
SI (2)	SI1227088T1 (is)
SK (1)	SK285528B6 (is)
TR (1)	TR200202185T2 (is)
UA (1)	UA74360C2 (is)
WO (1)	WO2001068627A1 (is)
YU (1)	YU68802A (is)
ZA (1)	ZA200207148B (is)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ514671A (en)	1999-04-14	2003-10-31	H	Method for the preparation of citalopram
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
US7713279B2 (en)	2000-12-20	2010-05-11	Fox Hollow Technologies, Inc.	Method and devices for cutting tissue
US7708749B2 (en)	2000-12-20	2010-05-04	Fox Hollow Technologies, Inc.	Debulking catheters and methods
US8328829B2 (en)	1999-08-19	2012-12-11	Covidien Lp	High capacity debulking catheter with razor edge cutting window
US7887556B2 (en)	2000-12-20	2011-02-15	Fox Hollow Technologies, Inc.	Debulking catheters and methods
US6299622B1 (en)	1999-08-19	2001-10-09	Fox Hollow Technologies, Inc.	Atherectomy catheter with aligned imager
NL1017417C1 (nl)	2000-03-03	2001-03-16	Lundbeck & Co As H	Werkwijze voor de bereiding van Citalopram.
NL1017500C1 (nl)	2000-03-13	2001-04-26	Lundbeck & Co As H	Werkwijze voor de bereiding van Citalopram.
GB2357762B (en) *	2000-03-13	2002-01-30	Lundbeck & Co As H	Crystalline base of citalopram
US6977306B2 (en) *	2000-05-02	2005-12-20	Sumitomo Chemical Company, Limited	Citalopram hydrobromide crystal and method for crystallization thereof
AR032455A1 (es)	2000-05-12	2003-11-12	Lundbeck & Co As H	Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
CA2353693C (en) *	2000-08-10	2003-07-22	H. Lundbeck A/S	Pharmaceutical composition containing citalopram
GB2376233B (en) *	2000-08-10	2003-09-10	Lundbeck & Co As H	Crystals of a pharmaceutically acceptable salt of citalopram wherein the median size of the crystals is at least 40 microns
DE60144107D1 (de)	2000-12-20	2011-04-07	Fox Hollow Technologies Inc	Verkleinerungskatheter
JP3798982B2 (ja) *	2000-12-22	2006-07-19	ハー・ルンドベック・アクチエゼルスカベット	純粋なシタロプラムの製造方法
AU2001100195B4 (en) *	2001-01-05	2001-12-20	H Lundbeck As	Pharmaceutical composition containing citalopram.
GB0105627D0 (en) *	2001-03-07	2001-04-25	Cipla Ltd	Preparation of phthalanes
EA200301195A1 (ru) *	2001-05-01	2004-04-29	Х. Лундбекк А/С	Применение энантиомерно чистого эсциталопрама
HRP20031073A2 (en)	2001-07-31	2004-04-30	Lundbeck & Co As H	Crystalline composition containing escitalopram
WO2003057132A2 (en) *	2002-01-07	2003-07-17	Sun Pharmaceutical Industries Limited	Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB2387844B (en) *	2002-02-27	2005-05-11	Matrix Lab Ltd	Separation of impurities from a crude mixture of citalopram
GB2386118A (en) *	2002-02-27	2003-09-10	Cipla Ltd	Citalopram
GB2386119A (en) *	2002-02-27	2003-09-10	Cipla Ltd	Purification of citalopram
GB0204607D0 (en)	2002-02-27	2002-04-10	Matrix Lab Ltd	Process
GB2385848A (en) *	2002-02-27	2003-09-03	Cipla Ltd	Citalopram salts
EP1346989A1 (en) *	2002-03-21	2003-09-24	Jubilant Organosys Limited	Improved process for the preparation of citalopram and its hydrobromide
GB0206708D0 (en) *	2002-03-21	2002-05-01	Cipla Ltd	Pharmaceutical salts
US6812355B2 (en)	2002-10-22	2004-11-02	Sekhsaria Chemicals Limited	Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
TR200504022T1 (tr) *	2003-03-24	2006-08-21	Hetero Drugs Limited	(S)-sitalopram oksalatın yeni sıvı kristal formları.
WO2004094399A1 (en) *	2003-04-21	2004-11-04	Natco Pharma Ltd	An improved process for the preparation of citalopram hydrobromide
US8246640B2 (en)	2003-04-22	2012-08-21	Tyco Healthcare Group Lp	Methods and devices for cutting tissue at a vascular location
US7019153B2 (en)	2003-06-10	2006-03-28	Sun Pharmaceutical Industries Limited	Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
GB0317475D0 (en) *	2003-07-25	2003-08-27	Meditab Specialities Pvt Ltd	Product
JP4025735B2 (ja) *	2003-08-21	2007-12-26	ロームアンドハースカンパニー	水性系を処理する方法
GB0320312D0 (en)	2003-08-29	2003-10-01	Novartis Ag	Purification process
CN100569765C (zh) *	2003-12-19	2009-12-16	杭州民生药业集团有限公司	西酞普兰中间体晶体碱
ITTO20050301A1 (it) *	2005-05-05	2006-11-06	Errekappa Euroterapici Spa	Formulazioni liquide orali contenenti citalopram
US20110196032A1 (en) *	2005-05-20	2011-08-11	Ashish Gogia	Pharmaceutical Dosage Form of an Antidepressant
TWI347942B (en) *	2005-06-22	2011-09-01	Lundbeck & Co As H	Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7834201B2 (en)	2005-06-22	2010-11-16	H. Lundbeck A/S	Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
RU2408368C2 (ru)	2005-06-27	2011-01-10	Биовэйл Лэборэториз Интернэшнл С.Р.Л.	Препараты соли бупропиона с модифицированным высвобождением
US20070276419A1 (en)	2006-05-26	2007-11-29	Fox Hollow Technologies, Inc.	Methods and devices for rotating an active element and an energy emitter on a catheter
US8784440B2 (en)	2008-02-25	2014-07-22	Covidien Lp	Methods and devices for cutting tissue
CN102223847B (zh)	2008-10-13	2013-10-30	泰科保健集团有限合伙公司	用于操纵导管轴的装置和方法
KR101323553B1 (ko)	2009-04-29	2013-10-29	코비디엔 엘피	조직을 절제하고 연마하기 위한 방법 및 장치
KR101581091B1 (ko)	2009-05-14	2015-12-30	코비디엔 엘피	세척이 용이한 죽상반 절제 카테터 및 사용 방법
EP2913013B1 (en)	2009-12-02	2016-11-09	Covidien LP	Methods and devices for cutting tissue
IN2012DN04977A (is)	2009-12-11	2015-09-25	Tyco Healthcare
WO2011159697A1 (en)	2010-06-14	2011-12-22	Tyco Healthcare Group Lp	Material removal device
WO2012058438A1 (en)	2010-10-28	2012-05-03	Tyco Healthcare Group Lp	Material removal device and method of use
RU2553930C2 (ru)	2010-11-11	2015-06-20	Ковидиен Лп	Гибкие фрагментирующие катетеры с визуализацией и способы их использования и изготовления
JP5806407B2 (ja)	2011-09-01	2015-11-10	コヴィディエンリミテッドパートナーシップ	螺旋駆動軸を有するカテーテルおよび製造方法
US9579157B2 (en)	2012-09-13	2017-02-28	Covidien Lp	Cleaning device for medical instrument and method of use
US9943329B2 (en)	2012-11-08	2018-04-17	Covidien Lp	Tissue-removing catheter with rotatable cutter
WO2015200702A1 (en)	2014-06-27	2015-12-30	Covidien Lp	Cleaning device for catheter and catheter including the same
US10314667B2 (en)	2015-03-25	2019-06-11	Covidien Lp	Cleaning device for cleaning medical instrument
US10292721B2 (en)	2015-07-20	2019-05-21	Covidien Lp	Tissue-removing catheter including movable distal tip
US10314664B2 (en)	2015-10-07	2019-06-11	Covidien Lp	Tissue-removing catheter and tissue-removing element with depth stop
US20240024288A1 (en)	2019-07-19	2024-01-25	Bioxcel Therapeutics, Inc.	Non-sedating dexmedetomidine treatment regimens
US11806334B1 (en)	2023-01-12	2023-11-07	Bioxcel Therapeutics, Inc.	Non-sedating dexmedetomidine treatment regimens

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2233970A (en) *		1941-03-04		Quinoline compound and process of
US2584429A (en) *	1950-12-29	1952-02-05	Rohm & Haas	1,1-diphenyl-4-tert.-amino-2-butyne-1-ols
GB1143703A (is) *	1965-03-18
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
GB1526331A (en)	1976-01-14	1978-09-27	Kefalas As	Phthalanes
IL63968A (en) *	1980-10-01	1985-10-31	Glaxo Group Ltd	Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4535186A (en) *	1983-04-19	1985-08-13	American Home Products Corporation	2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8419963D0 (en) *	1984-08-06	1984-09-12	Lundbeck & Co As H	Intermediate compound and method
GB8814057D0 (en) *	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
US5296507A (en) *	1990-09-06	1994-03-22	H.Lundbeck A/S	Treatment of cerbrovascular disorders
DK213290D0 (da)	1990-09-06	1990-09-06	Lundbeck & Co As H	Treatment of cerebrovascular disorders
CA2120874E (en) *	1994-04-08	2002-01-08	Keshava Murthy	Form of form 1 ranitidine
TR200000066T2 (tr) *	1997-07-08	2000-11-21	H. Lundbeck A/S	Sitalopram hazırlanması için yöntem.
UA62985C2 (en) *	1997-11-10	2004-01-15	Lunnbeck As H	A method for the preparation of citalopram
ES2149734T3 (es) *	1997-11-11	2003-02-16	Lundbeck & Co As H	Metodo para la preparacion de citalopram.
PL199423B1 (pl) *	1998-10-20	2008-09-30	Lundbeck & Co As H	Sposób wytwarzania citalopramu
NZ514671A (en)	1999-04-14	2003-10-31	H	Method for the preparation of citalopram
ITMI991581A1 (it)	1999-06-25	2001-01-15	Lundbeck & Co As H	Metodo per la preparazione di citalopram
ITMI991579A1 (it)	1999-06-25	2001-01-15	Lundbeck & Co As H	Metodo per la preparazione di citalopram
US6433196B1 (en) *	2000-02-17	2002-08-13	Sumika Fine Chemicals Co., Ltd.	Production method of citalopram, intermediate therefor and production method of the intermediate
GB2357762B (en) *	2000-03-13	2002-01-30	Lundbeck & Co As H	Crystalline base of citalopram
US6977306B2 (en) *	2000-05-02	2005-12-20	Sumitomo Chemical Company, Limited	Citalopram hydrobromide crystal and method for crystallization thereof

2000
- 2000-04-13 GB GB0105982A patent/GB2357762B/en not_active Expired - Fee Related
- 2000-04-18 HU HU0001581A patent/HU0001581D0/hu unknown
- 2000-04-20 DE DE20007303U patent/DE20007303U1/de not_active Ceased
- 2000-10-18 NL NL1016435A patent/NL1016435C1/nl not_active IP Right Cessation
- 2000-11-09 IT IT2000MI002425A patent/IT1319645B1/it active
- 2000-12-05 US US09/730,490 patent/US20010031784A1/en not_active Abandoned
2001
- 2001-01-25 FI FI20010156A patent/FI20010156A0/fi unknown
- 2001-01-26 HU HU0100450A patent/HU0100450D0/hu unknown
- 2001-02-05 GB GBGB0102797.8A patent/GB0102797D0/en not_active Ceased
- 2001-02-05 IS IS5841A patent/IS5841A/is unknown
- 2001-02-05 DK DK200100183A patent/DK173903B1/da not_active IP Right Cessation
- 2001-02-05 HU HU0100531A patent/HUP0100531A3/hu unknown
- 2001-02-06 NO NO20010619A patent/NO312031B1/no active IP Right Review Request
- 2001-02-07 IE IE20010109A patent/IES20010109A2/en not_active IP Right Cessation
- 2001-02-07 FI FI20010225A patent/FI109022B/fi active
- 2001-02-12 GR GR20010100074A patent/GR1003796B/el unknown
- 2001-02-20 DE DE10108042A patent/DE10108042A1/de not_active Withdrawn
- 2001-02-20 DE DE10164687A patent/DE10164687B4/de not_active Revoked
- 2001-02-20 DE DE20121240U patent/DE20121240U1/de not_active Ceased
- 2001-02-21 FR FR0102340A patent/FR2806086B1/fr not_active Expired - Fee Related
- 2001-02-21 NL NL1017413A patent/NL1017413C1/nl not_active IP Right Cessation
- 2001-02-22 CH CH00321/01A patent/CH691477A5/de not_active IP Right Cessation
- 2001-02-22 CH CH00580/01A patent/CH691537A5/de not_active IP Right Cessation
- 2001-02-28 DK DK02009350T patent/DK1227088T3/da active
- 2001-02-28 EP EP01909568A patent/EP1169314B2/en not_active Expired - Lifetime
- 2001-02-28 AR ARP010100934A patent/AR029811A1/es unknown
- 2001-02-28 CA CA002411732A patent/CA2411732A1/en not_active Abandoned
- 2001-02-28 CN CNB018093418A patent/CN1258530C/zh not_active Expired - Fee Related
- 2001-02-28 IL IL14733901A patent/IL147339A/en not_active IP Right Cessation
- 2001-02-28 EA EA200200972A patent/EA200200972A1/ru unknown
- 2001-02-28 YU YU68802A patent/YU68802A/sh unknown
- 2001-02-28 DE DE60100022T patent/DE60100022T3/de not_active Expired - Fee Related
- 2001-02-28 AT AT01909568T patent/ATE223396T1/de not_active IP Right Cessation
- 2001-02-28 PT PT01909568T patent/PT1169314E/pt unknown
- 2001-02-28 EP EP02009350A patent/EP1227088B1/en not_active Revoked
- 2001-02-28 WO PCT/DK2001/000137 patent/WO2001068627A1/en not_active Ceased
- 2001-02-28 SI SI200130031T patent/SI1227088T1/xx unknown
- 2001-02-28 MX MXPA02008793A patent/MXPA02008793A/es active IP Right Grant
- 2001-02-28 KR KR1020027012048A patent/KR20020080486A/ko not_active Ceased
- 2001-02-28 CA CA002360287A patent/CA2360287C/en not_active Expired - Lifetime
- 2001-02-28 IT IT2001MI000406A patent/ITMI20010406A1/it unknown
- 2001-02-28 SI SI200130001T patent/SI1169314T2/sl unknown
- 2001-02-28 BR BR0109373-8A patent/BR0109373A/pt not_active IP Right Cessation
- 2001-02-28 HR HRP20020756 patent/HRP20020756A2/hr not_active Application Discontinuation
- 2001-02-28 ES ES02009350T patent/ES2180471T3/es not_active Expired - Lifetime
- 2001-02-28 DK DK01909568T patent/DK1169314T3/da active
- 2001-02-28 UA UA2002097314A patent/UA74360C2/uk unknown
- 2001-02-28 PL PL36015801A patent/PL360158A1/xx not_active Application Discontinuation
- 2001-02-28 TR TR2002/02185T patent/TR200202185T2/xx unknown
- 2001-02-28 CN CNA2005100091603A patent/CN1680350A/zh active Pending
- 2001-02-28 ES ES01909568T patent/ES2173054T3/es not_active Expired - Lifetime
- 2001-02-28 DE DE60100786T patent/DE60100786T2/de not_active Revoked
- 2001-02-28 DE DE1227088T patent/DE1227088T1/de active Pending
- 2001-02-28 AU AU37252/01A patent/AU746664B2/en not_active Ceased
- 2001-02-28 JP JP2001567719A patent/JP2003527383A/ja active Pending
- 2001-02-28 PT PT02009350T patent/PT1227088E/pt unknown
- 2001-02-28 BE BE2001/0136A patent/BE1013210A3/fr not_active IP Right Cessation
- 2001-02-28 AT AT02009350T patent/ATE250050T1/de not_active IP Right Cessation
- 2001-02-28 SK SK1313-2002A patent/SK285528B6/sk unknown
- 2001-02-28 IL IL15807201A patent/IL158072A0/xx unknown
- 2001-03-05 CZ CZ2001808A patent/CZ292077B6/cs not_active IP Right Cessation
- 2001-03-07 AT AT0016601U patent/AT4364U1/de unknown
- 2001-03-09 ES ES200100548A patent/ES2159491B1/es not_active Expired - Fee Related
- 2001-07-26 AU AU2001100197A patent/AU2001100197B4/en not_active Expired
- 2001-09-14 SE SE0103046A patent/SE517136C2/sv not_active IP Right Cessation
2002
- 2002-01-23 NO NO20020356A patent/NO315851B1/no unknown
- 2002-03-12 SE SE0200730A patent/SE526022C2/sv not_active IP Right Cessation
- 2002-09-05 BG BG107065A patent/BG107065A/bg unknown
- 2002-09-05 ZA ZA200207148A patent/ZA200207148B/en unknown
- 2002-09-12 US US10/245,824 patent/US20030078442A1/en not_active Abandoned
2003
- 2003-12-19 US US10/741,553 patent/US20040132808A1/en not_active Abandoned
- 2003-12-30 US US10/750,049 patent/US20040167210A1/en not_active Abandoned
2005
- 2005-03-24 US US11/090,336 patent/US20050165092A1/en not_active Abandoned
- 2005-03-24 US US11/090,337 patent/US20050165244A1/en not_active Abandoned
2006
- 2006-06-20 US US11/425,321 patent/US20060247451A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CH691537A5 (de)	2001-08-15
DE10108042A1 (de)	2001-10-18
NO20020356D0 (no)	2002-01-23
CN1680350A (zh)	2005-10-12
DK1227088T3 (da)	2003-12-22
FI109022B (fi)	2002-05-15
US20010031784A1 (en)	2001-10-18
SI1169314T2 (sl)	2011-08-31
NO315851B1 (no)	2003-11-03
WO2001068627A1 (en)	2001-09-20
ITMI20010406A1 (it)	2002-08-28
HUP0100531A2 (hu)	2002-01-28
DE60100786T2 (de)	2004-07-15
IL147339A (en)	2004-09-27
EP1169314B2 (en)	2011-06-01
YU68802A (sh)	2005-11-28
EA200200972A1 (ru)	2003-02-27
HU0100450D0 (en)	2001-04-28
DE60100022D1 (de)	2002-10-10
SI1169314T1 (en)	2002-12-31
FI20010225L (fi)	2001-09-14
EP1227088A1 (en)	2002-07-31
SE526022C2 (sv)	2005-06-14
EP1169314A1 (en)	2002-01-09
DE60100786D1 (de)	2003-10-23
AT4364U1 (de)	2001-06-25
BE1013210A3 (fr)	2001-10-02
CZ2001808A3 (cs)	2002-01-16
EP1169314B1 (en)	2002-09-04
HU0001581D0 (en)	2000-06-28
CA2360287C (en)	2003-09-09
DE20007303U1 (de)	2000-07-27
GB2357762B (en)	2002-01-30
IS5841A (is)	2001-09-14
PT1227088E (pt)	2003-12-31
DK173903B1 (da)	2002-02-11
FI20010156A0 (fi)	2001-01-25
AU3725201A (en)	2001-09-13
ES2173054T1 (es)	2002-10-16
US20060247451A1 (en)	2006-11-02
AU746664B2 (en)	2002-05-02
CA2360287A1 (en)	2001-09-20
PT1169314E (pt)	2002-11-29
ATE250050T1 (de)	2003-10-15
NO312031B1 (no)	2002-03-04
DE20121240U1 (de)	2002-07-04
CN1429220A (zh)	2003-07-09
KR20020080486A (ko)	2002-10-23
US20040167210A1 (en)	2004-08-26
SE0200730L (sv)	2002-08-29
MXPA02008793A (es)	2003-02-12
BR0109373A (pt)	2002-12-24
GB0102797D0 (en)	2001-03-21
JP2003527383A (ja)	2003-09-16
GB0105982D0 (en)	2001-05-02
IT1319645B1 (it)	2003-10-23
TR200202185T2 (tr)	2002-12-23
CZ292077B6 (cs)	2003-07-16
EP1227088B1 (en)	2003-09-17
ITMI20002425A1 (it)	2002-05-09
ES2159491A1 (es)	2001-10-01
SE517136C2 (sv)	2002-04-16
HU0100531D0 (en)	2001-03-28
FI20010225A0 (fi)	2001-02-07
HUP0100531A3 (en)	2004-04-28
HK1054750A1 (en)	2003-12-12
AR029811A1 (es)	2003-07-16
ES2173054T3 (es)	2002-12-16
IL147339A0 (en)	2002-08-14
NL1016435C1 (nl)	2000-11-06
ES2159491B1 (es)	2002-05-01
GR1003796B (el)	2002-02-08
FR2806086A1 (fr)	2001-09-14
CH691477A5 (de)	2001-07-31
US20030078442A1 (en)	2003-04-24
HRP20020756A2 (en)	2004-12-31
PL360158A1 (en)	2004-09-06
SI1227088T1 (en)	2003-12-31
AU2001100197B4 (en)	2001-12-06
CA2411732A1 (en)	2001-09-20
GB2357762A (en)	2001-07-04
NO20010619L (no)	2001-09-14
DE60100022T2 (de)	2003-03-06
NL1017413C1 (nl)	2001-09-13
NO20010619D0 (no)	2001-02-06
DK1169314T3 (da)	2002-10-14
AU2001100197A4 (en)	2001-09-20
ES2180471T3 (es)	2004-05-01
FR2806086B1 (fr)	2003-05-09
IL158072A0 (en)	2004-03-28
SK13132002A3 (sk)	2003-01-09
US20050165244A1 (en)	2005-07-28
US20040132808A1 (en)	2004-07-08
CN1258530C (zh)	2006-06-07
SK285528B6 (sk)	2007-03-01
ATE223396T1 (de)	2002-09-15
SE0200730D0 (sv)	2002-03-12
NO20020356L (no)	2001-09-14
SE0103046D0 (sv)	2001-09-14
DE10164687B4 (de)	2006-04-27
DE60100022T3 (de)	2011-11-17
ZA200207148B (en)	2003-04-23
SE0103046L (sv)	2001-11-14
ES2180471T1 (es)	2003-02-16
UA74360C2 (uk)	2005-12-15
US20050165092A1 (en)	2005-07-28
IES20010109A2 (en)	2002-02-20
DE1227088T1 (de)	2003-02-06

Publication	Publication Date	Title
EP1227088B1 (en)	2003-09-17	Crystalline base of citalopram and hydrochoride or hydrobromide salt thereof
US20060229459A1 (en)	2006-10-12	Crystalline base of citalopram
HK1054750B (en)	2007-01-19	Crystalline base of citalopram
HK1084104A (en)	2006-07-21	Crystalline base of citalopram